ArticleBMC pharmacology & toxicology2025
Mechanistic exploration of bisphenol A in primary Sjögren's syndrome using network toxicology, molecular docking, molecular dynamics simulations and experimental validation.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Sjögren's syndrome (pSS) is a chronic autoimmune disorder marked by exocrine gland impairment and systemic manifestations. Environmental endocrine disruptors, including bisphenol A (BPA), have been associated with immunological dysregulation; however, their involvement in pSS is not well-defined. This study integrated network toxicology, molecular docking, molecular dynamics simulation, and in vitro validation to examine the potential effects of BPA on pSS. Bioinformatics investigation revealed 25 overlapping targets between BPA-associated genes and differentially expressed genes related to pSS, with CASP3, PTGS1, and PTGS2 identified as main possibilities. Molecular docking and molecular dynamics simulations validated robust and stable interactions of BPA with these proteins. Cellular studies with human submandibular gland epithelial cells demonstrated dose-dependent cytotoxicity of BPA, accompanied by substantial overexpression of CASP3, PTGS1, and PTGS2 at 1 µM exposure. The data indicate that BPA enhances apoptosis and inflammatory signaling in salivary gland cells, potentially contributing to pSS progression. This study provides mechanistic insight into how BPA may contribute to autoimmune disease development, highlighting its potential role in pSS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.